Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0108 • ACR Convergence 2024
Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)
Fernanda Oliveira de Andrade Lopes¹, Andreia Coimbra Sousa², Massimo Radin³, Gustavo Balbi⁴, Irene Cecchi³, Savino Sciascia⁵, Flavio Victor Signorelli⁶ and Danieli Andrade², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²University of São Paulo, São Paulo, SP, Brazil, ³University of Turin, Turin, Italy, ⁴Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, ⁵University of Turin, Torino, Turin, Italy, ⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
Abstract Number: 0124 • ACR Convergence 2024
Sexual Health Challenges in Primary Antiphospholipid Syndrome: Exploring Prevalence and Clinical Correlates
Jonathan Campos-Guzmán¹, María Espinosa-León², Iris Paola García Herrera¹, Iris Jazmín Colunga Pedraza³, Mariel Martínez-Ruiz¹, Ana Barrera-Vargas⁴, Guillermo Guaracha Basañez⁵ and javier Merayo Chalico⁶, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic thromboinflammatory disease with various forms of presentation. There is limited information on sexual function in patients with APS,…
Abstract Number: 1240 • ACR Convergence 2024
Living with Antiphospholipid Antibodies: A Photovoice Exploration
Francesca Cardwell¹, Susan J. Elliott², Paul S. Gibson³, Nancy Soliman⁴, Leslie Skeith⁴, Ann E. Clarke⁵ and Megan Barber⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of Calgary, Calgary, ON, Canada, ⁵Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: The diverse manifestations of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPLs) exert substantial but poorly understood impacts on the lives of those affected. This…
Abstract Number: 0109 • ACR Convergence 2024
Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Rohan Willis¹, Anne Tebo², Leslie Skeith³, Nina Kello⁴, H Michael Belmont⁵, Paul Fortin⁶, Guilherme Ramires de Jesús⁷, David Branch⁸, Michelle Petri⁹, Jason Knight¹⁰, Reyhan Kose Cobanoglu¹¹, Maria Laura Bertolaccini¹², Hannah Cohen¹³, Robert Roubey¹⁴, Doruk Erkan¹⁵ and Danieli Andrade¹⁶, and on behalf of APS ACTION, ¹University of Texas Medical Branch, Galveston, TX, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³University of Calgary, Calgary, ON, Canada, ⁴Northwell Health, Brooklyn, NY, ⁵NYU School of Medicine, New York, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁹Johns Hopkins University School of Medicine, Timonium, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, ¹²King's College London, London, United Kingdom, ¹³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of São Paulo, São Paulo, SP, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
Abstract Number: 0125 • ACR Convergence 2024
Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome
Emily Balczewski¹, Amala Ambati², Wenying Liang¹, Jacqueline Madison¹, Yu Zuo¹, Karandeep Singh³ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Toledo, OH, ³University of California -- San Diego, San Diego, CA
Background/Purpose: Electronic health record (EHR) data provide a widely available, inexpensive, and information-rich tool that is underutilized in the research of rare diseases like antiphospholipid…
Abstract Number: 1267 • ACR Convergence 2024
Antiphospholipid Antibody-related Clinical Manifestations Presenting During Childhood versus Adulthood: Descriptive Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jheel Pandya¹, Danieli Andrade², Ann E. Clarke³, Maria Tektonidou⁴, Vittorio Pengo⁵, Massimo Radin⁶, Jose Pardos-Gea⁷, Nina Kello⁸, Diana Paredes-Ruiz⁹, Mª Angeles Aguirre-Zamorano¹⁰, H Michael Belmont¹¹, Paul Fortin¹², Flavio Victor Signorelli¹³, TATSUYA ATSUMI¹⁴, Zhuoli Zhang¹⁵, Maria Efthymiou¹⁶, David Branch¹⁷, Giulia Pazzola¹⁸, Angela Tincani¹⁹, Ali Duarte-Garcia²⁰, Esther Rodriguez-Almaraz²¹, Michelle Petri²², Ricard Cervera²³, Bahar Artim Esen²⁴, Guillermo Pons-Estel²⁵, Hui Shi²⁶, Yu Zuo²⁷, Rohan Willis²⁸, Pierluigi Meroni²⁹, Robert Roubey³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³² and Doruk Erkan¹, and on behalf of APS ACTION, ¹Hospital for Special Surgery, New York, NY, ²University of São Paulo, São Paulo, SP, Brazil, ³Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁶University of Turin, Turin, Italy, ⁷Vall d'Hebron University Hospital, Barcelona, Spain, ⁸Northwell Health, Brooklyn, NY, ⁹Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ¹⁰IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶University College London, London, United Kingdom, ¹⁷University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁸Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ¹⁹ASST Spedali Civili-University of Brescia, Brescia, Italy, ²⁰Mayo Clinic, Rochester, MN, ²¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²²Johns Hopkins University School of Medicine, Timonium, MD, ²³Hospital Clinic de Barcelona, Barcelona, Spain, ²⁴Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁵CREAR, Rosario, Argentina, ²⁶Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), ²⁷University of Michigan, Ann Arbor, MI, ²⁸University of Texas Medical Branch, Galveston, TX, ²⁹IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases. Given autoimmune diseases present differently in…
Abstract Number: 0110 • ACR Convergence 2024
Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists
Rohan Willis¹, Vijaya Murthy², Karen Roye-Green³, Amy Thees⁴, May Choi⁵, Ken Dier⁶, Marvin Fritzler⁷, Susan Fink⁸, Vijayalakshmi Nandakumar⁹, Melissa Snyder¹⁰ and Anne Tebo¹¹, and the Association of Medical Laboratory Immunologists, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch (UTMB), League City, TX, ³University of the West Indies, Kingston, Jamaica, ⁴Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, ⁵University of Calgary, Calgary, AB, Canada, ⁶Corgenix, Broomfield, CO, ⁷Mitogen Diagnostics Corp, Calgary, AB, Canada, ⁸Clinical Immunology Laboratory, University of Washington Medical Center, Seattle, WA, ⁹ARUP/University of Utah, Salt Lake City, UT, ¹⁰Clinical Biochemistry and Immunology, Antibody Immunology Laboratory, Mayo Clinic, Rochester, MN, ¹¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: We have recently shown that anti-phospholipid (APL) assays of varying methodology demonstrate comparable analytical performance despite variable levels of agreement among individual analytes, identifying binding…
Abstract Number: 0126 • ACR Convergence 2024
Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data
Emily Balczewski¹, Amala Ambati², Wenying Liang¹, Jacqueline Madison¹, Yu Zuo¹, Karandeep Singh³ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Toledo, OH, ³University of California -- San Diego, San Diego, CA
Background/Purpose: Antiphospholipid syndrome (APS) is a rare autoimmune disease that is likely to demonstrate improved outcomes with earlier diagnosis and treatment. However, given APS’s complex,…
Abstract Number: 1556 • ACR Convergence 2024
Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis
Mohammad Taha¹, Yomna W Mahmoud¹, Mohammad Ramadan¹, sarah nasir¹, Mariam salah¹, Yassin shenawy², doaa gadelrab¹ and Muhammad abuawwad¹, and ARC team, ¹Cairo university, Cairo, Egypt, ²cairo, cairo, Egypt

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Anifrolumab is a monoclonal antibody that antagonizes type I interferon receptors,…
Abstract Number: 0111 • ACR Convergence 2024
Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria
Polona Zigon¹, Nika Bostič¹, Ziga Rotar², Ales Ambrozic³, Elizabeta Blokar³, Manca ogrič¹ and Sasa Cucnik¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana
Background/Purpose: Recently published 2023 ACR/EULAR APS classification criteria emphasize delineating moderate/high anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. The new criteria specify the use…
Abstract Number: 0127 • ACR Convergence 2024
Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China
Chen Chen¹, Ao Zhang², Jianhui Cheng³, Zhongqiang Yao⁴, Juan Meng⁵, Yilu Qin⁶, Qingyi Lu¹, Yufei Li¹, Xiangjun Liu¹, Tianhao Li⁷, Chao Hou⁷, Yundi Tang¹, Hongjiang Liu⁸, Ning Xu¹, Sai Dong¹, Xinxin Li³, Fangmin Xu², Jianping Guo¹ and Chun Li¹, ¹Peking University People's Hospital, Beijing, China, ²Beijing University of Posts and Telecommunications, Beijing, China, ³State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China (People's Republic), ⁴Peking University Third Hospital, Beijing, China, ⁵Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, ⁶Affiliated Xinxiang Central Hospital of Xinxiang Medical University, Xinxiang, China (People's Republic), ⁷Peking University Health Science Center, Beijing, China, ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…
Abstract Number: 1702 • ACR Convergence 2024
Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Naomi I. Maria², Zhengzi Yi³, Chirag Raparia⁴, Gayathri Konanur Gopikrishna¹, Weijia Zhang³ and Anne Davidson², ¹Feinstein Institutes for Medical Research, Manhasset, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Mt. Sinai School of Medicine, New York, NY, ⁴Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY
Background/Purpose: Antiphospholipid antibodies (aPL) confer a high risk for adverse pregnancy outcomes, especially in women with SLE. aPLs can induce pro-inflammatory signaling via TLR8 receptors,…
Abstract Number: 0112 • ACR Convergence 2024
Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts
Arne Vandevelde¹, Pierluigi Meroni², Hannah Cohen³, Danieli Andrade⁴, Olga Amengual⁵, TATSUYA ATSUMI⁵, Angela Tincani⁶, H Michael Belmont⁷, Maria Borghi⁸, David Branch⁹, Ricard Cervera¹⁰, Guilherme Ramires de Jesús¹¹, Paul Fortin¹², Jean-Christophe Gris¹³, Claudia Grossi⁸, Jason Knight¹⁴, Gary W. Moore¹⁵, Jacek Musiał¹⁶, Michelle Petri¹⁷, Esther Rodriguez-Almaraz¹⁸, Diana Paredes-Ruiz¹⁹, Robert Roubey²⁰, Anne Tebo²¹, Maria Tektonidou²², Denis WAHL²³, Stéphane Zuily²³, Rohan Willis²⁴, Vittorio Pengo²⁵, Maria Laura Bertolaccini²⁶, Doruk Erkan²⁷ and Katrien Devreese¹, ¹Department of Diagnostic Sciences, Ghent University and Coagulation Laboratory, Ghent University Hospital, Ghent, Belgium, ²IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴University of São Paulo, São Paulo, SP, Brazil, ⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁶ASST Spedali Civili-University of Brescia, Brescia, Italy, ⁷NYU School of Medicine, New York, NY, ⁸Immunorheumatology research laboratory, IRCCS Istituto Auxologico, Milan, Italy, ⁹University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁰Hospital Clinic de Barcelona, Barcelona, Spain, ¹¹Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹²Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹³Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France and Department of Hematology, Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France and UMR UA11 INSERM IDESP - Montpellier University, France and Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵Specialist Haemostasis Unit, Addenbrooke's Hospital, Cambridge, United Kingdom and Department of Natural Sciences, Middlesex University, London, United Kingdom, ¹⁶Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland, ¹⁷Johns Hopkins University School of Medicine, Timonium, MD, ¹⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁹Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ²⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ²¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ²²National and Kapodistrian University of Athens, Athens, Greece, ²³Lorraine University, Nancy, France, ²⁴University of Texas Medical Branch, Galveston, TX, ²⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ²⁶King's College London, London, United Kingdom, ²⁷Hospital for Special Surgery, New York, NY
Background/Purpose: Correlation of numerical values between the low, moderate, and high (L, M,H) levels of enzyme-linked immunosorbent assay (ELISA) and non-ELISA platforms for anticardiolipin antibody…
Abstract Number: 0128 • ACR Convergence 2024
Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study
Laura Aline Martinez-Martinez¹, Mary-Carmen Amigo² and María Victoria Goycochea Robles³, ¹Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, ²ABC Medical Center, Mexico City, Estado de México, Mexico, ³Universidad Nacional Autonoma de Mexico, Mexico city, Distrito Federal, Mexico
Background/Purpose: Antiphospholipid antibody syndrome is the main acquired thrombophilia in the rheumatological area. It is characterized by thrombotic events and obstetric morbidity associated with the…
Abstract Number: 2374 • ACR Convergence 2024
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Omer Uludag¹, Sarvan Aghamuradov¹, Cansu Erel Gezegen², Marjan Jabbarli², Ismat Habibov², Ahmet Oguz Celik², Yasemin Yalcinkaya¹, Ahmet Gul¹, Murat Inanc¹ and Bahar Artim Esen¹, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey
Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…

1
2
3
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.